Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 83.7% in July

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 9,551 shares, a decline of 83.7% from the July 15th total of 58,489 shares. Based on an average daily volume of 481,032 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Oncotelic Therapeutics Stock Performance

OTCMKTS:OTLC opened at $0.04 on Wednesday. Oncotelic Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.11. The business’s fifty day moving average is $0.04 and its 200 day moving average is $0.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.11 and a current ratio of 0.11. The firm has a market cap of $15.98 million, a price-to-earnings ratio of 0.06 and a beta of -0.23.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.